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Background: The effects of dyslipidemia on platelet reactivity in patients treated with optimal medical therapy (OMT) who undergo elective 
percutaneous intervention (PCI) have not been well studied.
methods: Demographic and clinical data were collected on 329 consecutive stable ischemic heart disease patients undergoing elective PCI (mean 
age: 63±12 years, female sex: 31%, hypertension: 73%, diabetes: 26%, current smoking: 22%) on OMT, which included: beta-blockers (96%), ACE 
inhibitor or ARB (72%), aspirin ± clopidogrel (97%), statin (76%), and additional dyslipidemic agents: niacin, fibrate, or ezetimibe (13%) at the time 
of PCI. Platelet function (PFA-100) testing was also performed; with a normal range of 80-184 sec. Statistical analyses included ANOVA, chi-square, 
and logistic regression tests for all comparisons.
results: Demographic parameters and cardiac risk factors had no significant effect on platelet reactivity. Similarly, total cholesterol, triglycerides, 
LDL, and HDL levels had no significant effect on platelet reactivity in patients treated with statins. Despite comparable cholesterol levels on statin 
vs. non-statin therapy, there was a trend towards decreased platelet inhibition with non-statin dyslipidemic therapy (248±74 sec in statin vs. 
230±81 sec in non-statin treated patients, P=0.073). In patients receiving non- statin therapy, platelet inhibition was significantly lower with fibrate 
treatment: niacin group n=6 (269 ±71 sec), ezetimibe n=29 (261±61 sec), fibrate n=8 (189±96 sec), p=0.034.
conclusions: In patients on OMT undergoing elective PCI, demographic parameters and cardiac risk factors have no significant effect on platelet 
reactivity. Despite comparable effects on cholesterol and LDL levels, concomitant non-statin dyslipidemic therapy appears to be associated with 
less complete platelet inhibition. This finding may potentially explain superior clinical outcomes associated with statin treatment and underscores 
importance of evidence-based therapy in CAD patients.
